PACAP (1-38) (human, mouse, ovine, porcine, rat) (trifluoroacetate salt)

Pituitary adenylate cyclase-activating peptide (PACAP) (1-38) is a PACAP receptor agonist with IC50 values of 4, 2, and 1 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expressed in CHO cells.1 It binds to PACAP receptors in rat brain membrane (IC50 = 4.45 nM) and to SH-SY5Y and SK-N-MC human neuroblastoma and T47D human breast cancer cells (IC50s = 3.6, 13, and 4.7 nM, respectively).2,3 It also stimulates cAMP accumulation in H-SY5Y, SK-N-MC, and T47D cells (EC50s = 0.37, 0.26, and 0.73 nM, respectively).3 In vivo, in newborn pigs, PACAP (1-38) (1 μM) induces vasodilation of pial arterioles by 43%.4WARNING This product is not for human or veterinary use.

[1] PHILIPPE GOURLET. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors[J]. European journal of pharmacology, 1995, 287 1: Pages 7-11. DOI: 10.1016/0014-2999(95)00467-5
[2] O MORO. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist.[J]. The Journal of Biological Chemistry, 1999, 274 33: 23103-23110. DOI: 10.1074/jbc.274.33.23103
[3] M. EGGENBERGER . Maxadilan interacts with receptors for pituitary adenylyl cyclase activating peptide in human SH-SY5Y and SK-N-MC neuroblastoma cells[J]. Neuropeptides, 1999, 33 2: Pages 107-114. DOI: 10.1054/npep.1999.0004
[4] LAURA LENTI . Pituitary adenylate cyclase-activating polypeptide induces pial arteriolar vasodilation through cyclooxygenase-dependent and independent mechanisms in newborn pigs[J]. Brain Research, 2007, 1165: Pages 81-88. DOI: 10.1016/j.brainres.2007.06.032